FIELD: medicine.
SUBSTANCE: invention can be applied for treatment of patients with bronchial asthma of medium-severe or severe clinical course in phase of exacerbation with high risk of sinus tachycardia development. If high risk of sinus tachycardia development is determined, ivabradine is introduced in standard complex of treatment, which includes beta2-agonists. Medicine is used during all exacerbation period in daily doze 10-14 mg.
EFFECT: method allows to increase treatment safety and efficiency of correcting side effect of high doses of beta2-agonists.
2 cl, 10 tbl, 2 ex
Title | Year | Author | Number |
---|---|---|---|
METHOD OF TREATING BRONCHIAL ASTHMA IN CHILDREN | 2009 |
|
RU2417802C2 |
METHOD OF CHRONIC OBSTRUCTIVE LUNG DISEASE (BRONCHIAL ASTHMA, CHRONIC OBSTRUCTIVE LUNG DISEASE) MEDICAL TREATMENT | 2006 |
|
RU2326647C2 |
METHOD FOR PREDICTION OF PROGRESSION OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) | 2015 |
|
RU2599349C1 |
METHOD OF INTERGRATED TREATMENT OF REMITTED CHRONIC OBSTRUCTIVE PULMONARY DISEASE | 2008 |
|
RU2386438C1 |
METHOD FOR IMPROVEMENT OF SPUTUM EXPECTORATION | 2016 |
|
RU2609992C1 |
METHOD OF TREATING CHRONIC OBSTRUCTIVE PULMONARY DISEASE | 2015 |
|
RU2600833C1 |
METHOD OF PREOPERATIVE PREPARATION OF PATIENTS WITH THYROTOXICOSIS | 2010 |
|
RU2469725C2 |
METHOD FOR PREDICTION OF AGGRAVATED BRONCHIAL ASTHMA DURATION | 2010 |
|
RU2446400C1 |
METHOD OF ESTIMATION OF MICROVASCULAR ENDOTHELIUM STATUS IN PATIENTS WITH BRONCHIAL ASTHMA | 2010 |
|
RU2436091C1 |
METHOD FOR PREDICTION OF RISK OF DEVELOPING LIFE THREATENING COMPLICATIONS IN PATIENTS WITH MYOCARDIAL INFARCTION WITH BACKGROUND OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE | 2019 |
|
RU2740896C1 |
Authors
Dates
2010-03-10—Published
2008-08-07—Filed